"Cytochrome P-450 CYP2D6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
| Descriptor ID |
D019389
|
| MeSH Number(s) |
D08.244.453.005.600 D08.244.453.491.372 D08.811.682.690.708.170.010.600 D08.811.682.690.708.170.450.368 D12.776.422.220.453.010.600 D12.776.422.220.453.491.368
|
| Concept/Terms |
Cytochrome P-450 CYP2D6- Cytochrome P-450 CYP2D6
- CYP2D6, Cytochrome P-450
- Cytochrome P 450 CYP2D6
- P-450 CYP2D6, Cytochrome
- Sparteine Monooxygenase
- Monooxygenase, Sparteine
- Cytochrome P450 2D6
- P450 2D6, Cytochrome
- Debrisoquine 4-Monooxygenase
- 4-Monooxygenase, Debrisoquine
- Debrisoquine 4 Monooxygenase
- Imipramine 2-Hydroxylase
- 2-Hydroxylase, Imipramine
- Imipramine 2 Hydroxylase
- CYP2D6
- CYP 2D6
- Debrisoquine 4-Hydroxylase
- 4-Hydroxylase, Debrisoquine
- Debrisoquine 4 Hydroxylase
- Debrisoquine Hydroxylase
- Hydroxylase, Debrisoquine
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6" by people in this website by year, and whether "Cytochrome P-450 CYP2D6" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 3 | 1 | 4 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 6 | 0 | 6 |
| 2002 | 3 | 1 | 4 |
| 2003 | 4 | 1 | 5 |
| 2004 | 3 | 3 | 6 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 3 | 4 |
| 2007 | 2 | 2 | 4 |
| 2008 | 3 | 4 | 7 |
| 2009 | 2 | 0 | 2 |
| 2010 | 6 | 1 | 7 |
| 2011 | 3 | 2 | 5 |
| 2012 | 3 | 4 | 7 |
| 2013 | 9 | 2 | 11 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 3 | 4 |
| 2019 | 3 | 1 | 4 |
| 2020 | 4 | 5 | 9 |
| 2021 | 4 | 3 | 7 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 1 | 3 |
Below are the most recent publications written about "Cytochrome P-450 CYP2D6" by people in Profiles.
-
Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression. Clin Transl Sci. 2024 Jun; 17(6):e13822.
-
The genomic landscape of CYP2D6 variation in the Indian population. Pharmacogenomics. 2024 Feb; 25(3):147-160.
-
Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study. J Child Adolesc Psychopharmacol. 2024 02; 34(1):42-51.
-
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0068323.
-
CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial. Pharmacotherapy. 2023 Dec; 43(12):1286-1296.
-
Preemptive Pharmacogenetic-Guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery: The Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery Pilot Trial. J Cardiothorac Vasc Anesth. 2023 10; 37(10):1974-1982.
-
Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens. Clin Pharmacol Ther. 2023 07; 114(1):69-76.
-
Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma. Drug Metab Pers Ther. 2023 06 01; 38(2):143-148.
-
Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder. J Psychopharmacol. 2022 Oct; 36(10):1146-1150.
-
Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genet Med. 2022 05; 24(5):1062-1072.